Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROMETHAMINE vs PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
Metabolic acidosis associated with cardiac arrest,Correction of metabolic acidosis in acute respiratory acidosis,Metabolic acidosis in renal failure,Metabolic acidosis in diabetes mellitus
FDA: Treatment of hyperuricemia associated with gout (prophylaxis and chronic management), adjunct to penicillin or cephalosporin therapy to elevate and prolong antibiotic levels.,Off-label: Prevention of nephropathy in patients with hyperuricemia, adjunct to antiviral agents (e.g., cidofovir) to reduce nephrotoxicity.
Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
Terminal elimination half-life: 2–3 hours in adults with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Tromethamine is not metabolized; it is primarily excreted unchanged by the kidneys.
Primarily hepatic via oxidation and glucuronidation; minor renal metabolism.
Renal excretion of unchanged drug: >95%. Negligible biliary or fecal elimination.
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
<10% bound to plasma proteins (albumin).
Approximately 75-95% bound to plasma albumin.
0.3–0.4 L/kg; primarily distributes in extracellular fluid.
Apparent volume of distribution is about 9 L (approximately 0.13 L/kg in adults); indicates limited extravascular distribution, primarily confined to plasma and extracellular fluid.
Not available (administered intravenously only; oral bioavailability is negligible due to lack of absorption).
Oral bioavailability is nearly complete (>90%) with peak plasma concentrations achieved within 2-4 hours.
Contraindicated in anuria or severe renal impairment (GFR < 30 m L/min). Use with caution in renal insufficiency; monitor acid-base balance. No specific dose adjustment guidelines; avoid in renal failure.
GFR 10-50 m L/min: 250 mg once daily or 500 mg every 12-24 hours; GFR <10 m L/min: avoid use; anuria: contraindicated.
No specific Child-Pugh based dose adjustments; use with caution in hepatic impairment as metabolism is minimal (primarily renal excretion). Monitor electrolytes and p H.
No specific adjustment recommended; use caution in severe hepatic impairment.
Intravenous: 1 M solution; dose based on calculated base deficit: m L of 0.3 M THAM = body weight (kg) × base deficit (m Eq/L) × 1.1. Administer over 1-2 hours via central line. Maximum infusion rate: 5 m L/kg/hour.
For gout or hyperuricemia (children >2 years): 25 mg/kg/day (max 2 g/day) divided every 6-8 hours; as adjunct to penicillin/cephalosporin: 25 mg/kg/day (max 2 g/day) divided every 8 hours for infants >3 months and children; neonates: dose not established.
No specific dose adjustment; monitor renal function and avoid in geriatric patients with renal impairment due to decreased creatinine clearance. Use lower end of dosing range and monitor acid-base status frequently.
Start at lowest dose (250 mg once daily) due to age-related renal impairment; monitor renal function regularly; avoid if GFR <30 m L/min.
There is no FDA black box warning for tromethamine.
None.
Monitor blood p H, p CO2, and electrolytes (especially potassium) during infusion,Use with caution in patients with renal impairment due to risk of accumulation,May cause respiratory depression, especially in patients with impaired renal function,Avoid extravasation due to tissue necrosis,Not recommended for neonatal use due to risk of hyperosmolality
Use with caution in patients with peptic ulcer disease.,May worsen acute gouty arthritis; prophylactic colchicine or NSAIDs recommended during initiation.,Risk of uric acid stone formation; ensure adequate hydration and alkalinize urine if needed.,Avoid use in patients with blood dyscrasias or bone marrow depression.,May interfere with urine glucose and ketone tests.
Anuria or uremia,Chronic respiratory acidosis,Hypoglycemia,Hyperkalemia,Hypocalcemia,Known hypersensitivity to tromethamine
Hypersensitivity to probenecid or any component.,Severe renal impairment (Cr Cl <50 m L/min) or anuria.,History of uric acid kidney stones.,Concomitant use with methotrexate (increases methotrexate toxicity).,Use during acute gouty attack (unless already on therapy).
No known food interactions. However, electrolyte imbalances (e.g., hypokalemia) may be affected by dietary potassium intake; maintain a balanced diet per clinician advice.
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat) as they increase uric acid levels. Limit alcohol, especially beer and spirits, which increase uric acid. Maintain high fluid intake (water, citrus juices) to promote urine flow and prevent stones. Avoid cranberry juice as it may acidify urine.
Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause fetal harm when administered to a pregnant woman. Use during pregnancy only if clearly needed. Risk cannot be ruled out.
Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known teratogenic effects. Second and third trimesters: No specific fetal risks documented; avoid near term due to potential for neonatal hyperbilirubinemia (displaces bilirubin from albumin).
It is not known whether tromethamine is excreted in human milk. The M/P ratio is undetermined. Caution should be exercised when administered to a nursing woman.
Probenecid is excreted into breast milk in low concentrations; M/P ratio not available. Consider benefits of breastfeeding versus potential risk of adverse effects in infant (e.g., rash, gastrointestinal effects). Use with caution.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered renal function) may necessitate careful monitoring and titration based on clinical and laboratory response.
No formal pharmacokinetic studies during pregnancy. Dose adjustment not routinely recommended, but consider decreased efficacy due to increased renal clearance in pregnancy. Monitor clinical response and adjust dose if needed.
Tromethamine (THAM) is an amino alcohol that acts as a proton acceptor, used to correct metabolic acidosis when sodium bicarbonate is contraindicated (e.g., hypernatremia, hypercapnia). It is preferred in patients with lactic acidosis or respiratory acidosis because it does not generate CO2. Monitor serum potassium closely as it can cause hypokalemia. Extravasation causes tissue necrosis; administer via central line if possible. Correct dosing is based on base deficit: m L of 0.3 M THAM = base deficit (m Eq/L) × weight (kg) × 1.1.
Probenecid inhibits renal tubular secretion of uric acid, increasing its excretion; used for chronic gout, not acute attacks. It also reduces renal excretion of penicillins and cephalosporins, so it is used to increase serum levels of these antibiotics. Ensure adequate hydration (at least 2-3 L daily) to prevent urate nephropathy. Avoid in patients with creatinine clearance <50 m L/min, history of uric acid stones, or acute gout attack. Alkalinization of urine (urine p H 6.5-7) reduces stone risk. Monitor serum uric acid, renal function, and CBC. Drug interactions: potentiates toxicity of methotrexate, NSAIDs, thiazides, salicylates (salicylates antagonize uricosuric effect).
This medication is used to treat acidosis (too much acid in the blood).,It is given intravenously (IV) by your healthcare provider.,Report any signs of IV site reaction: pain, redness, swelling, or blistering.,You may need frequent blood tests to monitor your acid-base balance and potassium levels.,Tell your doctor if you have kidney disease or low blood potassium before treatment.
Take probenecid with food or antacids to reduce GI upset.,Drink at least 8-10 glasses of water daily while on this medication.,Do not take aspirin or other salicylates; they can reduce the effect.,This drug may increase bleeding risk if you take blood thinners like warfarin.,Report any signs of allergic reaction, rash, or fever immediately.,Avoid alcohol as it increases uric acid levels.,Tell your doctor before taking other medications, especially antibiotics.,Do not use during an acute gout attack; wait until attack resolves.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Store at room temperature, away from moisture and heat.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROMETHAMINE vs PROBENECID, answered by our medical review team.
TROMETHAMINE is a Alkalinizing Agent (Buffer) that works by Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.. PROBENECID is a Uricosuric that works by Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROMETHAMINE and PROBENECID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROMETHAMINE is: Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.. The standard adult dose of PROBENECID is: Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROMETHAMINE and PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROMETHAMINE is classified as Category C. Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause feta. PROBENECID is classified as Category A/B. Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.